MedWatch

Y-mabs CEO resigns with immediate effect

On Wednesday, Claus Møller has exited the executive management of Y-mabs, and company’s founder, Thomas Gad, steps in as interim CEO until a replacement has been found. A new chair has also been appointed.

Photo: Kelly Davidson Photography

Danish-American biotech firm Y-mabs is on the lookout for a new chief executive as the man in charge up to now, Claus Møller, has announced his departure from the role effective immediately, a company press release announced on Wednesday.

The exit has caused a management reshuffle, as the company’s founder and chairman of the board, Thomas Gad, assumes the role of interim CEO until a replacement has been found.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs